VANCOUVER, BC / ACCESSWIRE / May 20, 2016 / Verisante Technology, Inc. (VRS.V) (OTC Pink: VRSEF) (the "Company" or "Verisante"), a leader in skin cancer detection technology, provides an operational update after releasing its financial statements for the year ended December 31, 2015.
The Company has begun a program in British Columbia of placing Aura™, a device for the detection of skin cancer, with local partner clinics. Currently, members of the public can visit the following clinics in British Columbia for an AuraScan™ and skin cancer screening services:
MD Wellness Solutions
#313-2626 Croydon Drive
Surrey, BC
Tel. (604) 385-3838
Mainland Medical Clinic
1061 Hamilton Street
Vancouver, BC
Tel. (604) 683-3973
Lakeshore Vein & Aesthetics Clinic
3293 Lakeshore Road
Kelowna, BC
Tel. (250) 860-9919
Verisante plans to continue to partner with suitable clinics in British Columbia to increase the number of Aura™ devices available to the public. Doctors or clinics who may be interested in becoming a partner with the Company are encouraged to contact Verisante directly for more information.
In addition to the Aura™ devices recently placed in British Columbia, the Company continues to support the devices previously placed across the country including the Medcan Clinic in Toronto,Medpoint Health Care Centre in London, Ontario, and at Dr. Barry Lycka's Dermasurgery clinic in Edmonton.
Verisante has further streamlined its production and manufacturing facilities and personnel to ensure the Company moves forward with the most cost-effective and efficient operations. The Company has reduced General and Administrative expenses by 47% during the year ended December 31, 2015 as compared to the same period the previous year.
Verisante is also continuing to work on obtaining US FDA approval for the Aura which is already approved in Canada and has a CE Mark. The Company has held two teleconference calls with the FDA and received guidance in regards to what steps need to be taken to obtain market clearance for the United States.
The Company is also in negotiations with a private lender for a long term debt financing of $3 million with additional equity financing that will assist Verisante in meeting our business and operational goals